Registration Deadline:
Event Contact:
More Information:
Explore other Industry Opportunities:
BSM Biotech Holding supports researchers, inventors, and founders in the biotech space worldwide to found, build, and grow biotech companies with the potential to establish new standards of care. The company is seeking innovative discovery research projects targeting neurodegeneration, with the aim of working with innovators to form new companies based on this research. Projects should be under preparation for IP filing or have IP already filed, allowing for asset protection in the USA, Europe, and Japan as a minimum.
Approaches of interest:
- Therapeutics targeting neurodegenerative diseases including dementia-related disorders, Parkinsonism and movement disorders, and motor neuron diseases
- All modalities except those listed below, including mAbs, small molecules, aptamers, bi/trispecific molecules, and modalities regulating gene expression
- All mechanisms of action and delivery routes
Out of scope:
- Cell and gene therapy
- Medical devices, diagnostics, and nutrition
- Drug repurposing and reformulation
- Developmental stage of interest: Opportunities should have, at minimum, a lead drug compound to late preclinical research. In vitro validation is preferred; in vivo validation is also desirable.
Summaries generated by AI. Please see attached documentation or email Cameron Sargent, CTTC Licensing Officer, for more information.
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.